You searched for "AMN"

1421 results found

The effects of anti-VEGF therapy for NvAMD on retinal vasculature

This retrospective consecutive case series examined 54 eyes of 54 treatment-naïve neovascular age-related macular degeneration (N-AMD) patients. Thirty-three eyes received intravitreal aflibercept injections, and 21 eyes received intravitreal ranibizumab injections with unaffected fellow eyes (54 eyes) as controls. All image...

Exploring the potential of neurodegenerative disease screening within age-related eye disease research

The authors recruited healthy controls aged between 60 and 75-years-old, previously enrolled into a registry as patients following cataract surgery without age-related macular degeneration (AMD). Exclusion criteria included dense cataract, retinal disease, ocular inflammatory disease, moderate glaucoma, optic neuropathy, cancer,...

Heidelberg Engineering joins the Collaborative Community on Ophthalmic Innovation (CCOI) through EssilorLuxottica’s Vision Architect membership

Heidelberg Engineering announced that it is joining the Collaborative Community on Ophthalmic Innovation (CCOI) as part of its parent company EssilorLuxottica’s Vision Architect membership – CCOI’s highest level of industry participation. CCOI is a public–private forum that convenes patients, clinicians,...

Technology in ophthalmology – a promising future and what we need to know about the regulations

Undoubtedly, ophthalmology is one of the greatest sources of inspiration for technological progress in medicine. Thus far, we have seen remarkable advancements in the technology used by ophthalmologists across all subspecialties. From simplifying common procedures, to treating previously incurable conditions,...

Shifting the paradigm of managing patients in medical retina: how real-world data can help us to improve clinical practice

The ophthalmic subspecialty of ‘medical retina’ has undergone dramatic changes in recent years. With the introduction of ranibizumab (Lucentis, Novartis), a specialty formerly dominated by laser-based therapies has been transformed to become, in large part, pharmacotherapy-based. To date, these pharmacotherapies...

Rare eye diseases: progress continues with authorised orphan medicines and breakthrough technologies

An update on the development of orphan medicines, recent regulatory treatment approvals for rare eye conditions and advances in retinal prosthetic technologies for blinding diseases. The prevalence of a rare disease is based usually on a range of estimates and...

Optos announces new ultra-widefield colour image modality, providing additional retinal visualisation to eyecare professionals

Optos, Plc, the leading retinal imaging company, announces it is expanding the optomap® ultra-widefield (UWF™) retinal imaging modalities available with the California FA device to further assist eyecare professionals in disease management and treatment planning.

Independent opticians shortlisted for the 2023 SightCare Awards

28 deserving independent optical practices have been shortlisted in their chosen categories of the 2023 SightCare Independent Optician Awards celebrating the independent spirit.

CHEC Wandsworth welcomes Marsha de Cordova MP to discuss her National Eye Health Strategy Bill

CHEC, a community healthcare provider delivering specialist ophthalmology services in partnership with the NHS, recently welcomed Marsha de Cordova, Labour MP for Battersea, to its new site in Wandsworth (Friday 17th Jan 2025) to share insights on how independent eyecare...

UK Eye Care Data Hub updated with additional eye conditions

The UK Eye Care Data Hub, the most up-to-date and comprehensive model of the UK’s eyecare workforce and eye diseases in one place, has been expanded to almost double the number of eye conditions and update aspects of the sector...

Newmedica Suffolk team completes half marathon in sight loss simulation glasses to support local charity

A team of eye health professionals has completed a half marathon wearing sight loss simulation glasses, raising funds and awareness for local charity Suffolk Sight. The group from ophthalmology provider Newmedica Suffolk completed the 13.1-mile Orwell Challenge on 28 June...

Emerging therapies for geographic atrophy: complement inhibitors show potential to slow progression and preserve RPE and photoreceptor integrity

Geographic atrophy (GA) is an advanced form of age-related macular degeneration (AMD) characterised by progressive, irreversible loss of the retinal pigment epithelium (RPE) and photoreceptors and is estimated to account for approximately 10% of AMD-related blindness [1-4]. The Age-Related Eye...